Table 2.
Successful virus clearance from LCMV-WE carrier mice requires d60 immune B cells
| Combination of transferred lymphocytes* (CD4/CD8/B) | Virus titer†
|
NAb titers‡ | |||
|---|---|---|---|---|---|
| Blood | Brain | Spleen | Kidney | ||
| Unseparated spleen cells (d60) | <1.7 | <2.0 | <2.0 | 4.7 ±0.5 | 3/3 |
| d8/d60/d60 | <1.7 | <1.8 | <2.0 | 3.8 ± 0.4 | 3/3 |
| d8/—/d60 | <1.7 | <2.0 | <2.0 | 4.6 ± 0.3 | 3/3 |
| d60/d8/d8 | 3.9 ± 0.3 | 4.8 ± 0.5 | 4.5 ± 0.5 | 5.5 ± 0.6 | 0/3 |
| d60/—/d8 | 4.2 ± 0.5 | 4.7 ± 0.2 | 4.2 ± 1.1 | 5.7 ± 0.4 | 0/3 |
Spleen cells from mice infected i.v. with 200 pfu of LCMV-WE either 8 or 60 days previously were depleted of CD4+ or CD8+ T cells or B cells or positively selected for CD4+ or CD8+ T cells or B cells using magnetic beads. Then, 5 × 106 CD4+ T cells, 5 × 106 CD8+ T cells, and 1 × 107 B cells from d8 or d60 immune spleens were injected in various combinations (cell order shown is CD4/CD8/B cells) into LCMV-WE-carrier mice according to the experimental setups listed in the table.
Virus titers are expressed as plaque-forming units per milliliter of blood or gram of organ (log10) on day 40 after cell transfer and are means ± SEM of three mice. The experiments were repeated at least three times with similar results.
Neutralizing antibody (NAb) titers were monitored 15–30 days after adoptive transfer, and numbers of mice displaying titers >2 log2 per total number of mice are given in the table.